Fowl adenovirus serotype 4 (FAdV-4) is recognized as the primary causative agent of hepatitis–hydropericardium syndrome (HHS), a devastating disease in poultry characterized by high mortality, severe hepatic lesions, and significant economic losses in the poultry industry worldwide (
27,
28). Despite the availability of conventional vaccines, controlling FAdV-4 remains challenging because vaccine-induced protection can be inconsistent owing to antigenic variation among circulating strains, incomplete immune responses, and reduced effectiveness against field outbreaks (
30). Moreover, inactivated and live-attenuated vaccines pose biosafety concerns, including the potential reversion of attenuated strains and the limited duration of protective immunity (
30). Therefore, alternative antiviral strategies, particularly gene therapy–based approaches, have become increasingly important in recent years.
RNA interference (RNAi) has emerged as a potent antiviral tool because it can specifically silence viral gene expression through endogenous cellular pathways (
31). Unlike vaccines or conventional drugs, RNAi strategies directly target viral mRNA transcripts, thereby reducing the risk that resistant escape variants will develop when conserved viral genes are selected as targets. In this study, we selected the DNA polymerase PHA02563 domain of FAdV-4 because this gene is essential for viral genome replication and is highly conserved across adenovirus serotypes (
32,
33). Targeting such conserved replication-associated genes increases the likelihood of achieving broad-spectrum antiviral efficacy while minimizing viral adaptation.
Lentiviral vectors were used in this study to deliver the DNA polymerase PHA02563 fragment into chicken embryo kidney (CEK) cells. Lentiviral vectors are widely recognized as efficient and relatively safe vehicles for stable gene delivery. Compared with transient plasmid-based systems, lentiviral vectors integrate the transgene into the host genome, enabling long-term expression (
34). Furthermore, they can transduce both dividing and nondividing cells, have high cloning capacity, and exhibit relatively lower immunogenicity than adenoviral or retroviral vectors (
35,
36).
However, the biological system generated in the present study should be interpreted as a puromycin-selected, lentiviral transgene-expressing CEK cell population rather than as a fully characterized, immortal stable cell line. This distinction is important for accurately interpreting the persistence and stability of expression.
In our study, successful co-expression of GFP confirmed that the DNA polymerase fragment was properly cloned upstream of the reporter gene and efficiently delivered into CEK cells by lentiviral transduction. Quantitative transduction efficiencies of approximately 85% at 48 h and 95% at 72 h across biological replicates support the robustness and reproducibility of the delivery system. This system provides a reliable and reproducible platform for downstream antiviral screening assays.
Comparable approaches have been used successfully in aquaculture and mammalian systems to evaluate antiviral RNAi strategies. Ruiz et al. developed fish cell lines expressing the viral hemorrhagic septicemia virus (VHSV) L gene and identified siRNAs capable of significantly reducing viral replication in vitro (
37). Similarly, Kim et al. engineered epithelioma papulosum cyprini (EPC) cells expressing VHSV-G to test shRNA constructs, which effectively suppressed gene expression (
38). Xu et al. demonstrated that RNAi could specifically silence the VP28 gene of white spot syndrome virus (WSSV) in shrimp by establishing a cell line that stably expressed the viral protein (
39). These studies highlight the value of stable or stably maintained transgene-expressing cell systems for identifying and validating RNAi-based antivirals before in vivo application.
The CEK cell system generated in this study therefore represents an important experimental platform for RNAi screening against FAdV-4. It provides a controlled in vitro environment for evaluating siRNA and shRNA constructs targeting the DNA polymerase gene and enables assessment of silencing efficiency, durability of inhibition, and potential off-target effects. Confirmation of transcriptional expression by RT-PCR (738 bp amplicon) further validates that the inserted viral fragment is transcriptionally active in the selected CEK population. Importantly, this model may facilitate medium-throughput RNAi screening and accelerate the identification of candidate antiviral molecules.
Nevertheless, several limitations of the present study should be acknowledged. First, although the recombinant construct and expression of the target transcript were confirmed by molecular analyses, protein-level validation was not performed. Therefore, expression of the PHA02563 domain at the protein level could not be directly confirmed. Second, the antiviral efficacy of the established CEK cell population was not evaluated using FAdV-4 infection or RNA interference-based inhibition assays in the present study. Thus, the practical antiviral performance of this system remains to be validated in future functional studies. In addition, the long-term stability of transgene expression and maintenance of the selected cell population over extended passages were not systematically evaluated. Therefore, the established system should be considered a puromycin-selected CEK cell population developed as a preliminary screening platform rather than a fully validated antiviral cell line. Future studies involving protein-level confirmation, long-term stability assessment, and functional evaluation using FAdV-4 infection and RNAi-mediated inhibition will be required to further validate and optimize this platform.
Finally, the present study should be regarded primarily as a proof-of-concept platform development study rather than a complete antiviral validation study. The functional antiviral efficacy of RNAi constructs was not assessed, and protein-level expression analysis was not performed; these issues should be addressed in future work.
5.1. Conclusions
In conclusion, the present study successfully established a puromycin-selected CEK cell population stably expressing the conserved domain of the FAdV-4 DNA polymerase gene using a lentiviral vector system. This engineered puromycin-selected CEK cell population provides a platform for RNAi-based antiviral screening against FAdV-4 and may serve as a foundation for developing therapeutic and preventive strategies for avian adenovirus infections.
Future studies should evaluate multiple RNAi constructs, optimize in vivo delivery strategies, and integrate RNAi with existing control measures to improve disease management in poultry.
Importantly, although stable selection pressure was applied using puromycin encoded in the transfer vector, stability during extended passage was not analyzed in this study; therefore, the long-term stability of the generated cell population remains to be validated.